Abstract
1184MO Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have